Pharsight

1. List of Inomax drug patents

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US8282966	March, 2016	Terminated-Denied	Mallinckrodt Hospital Products IP Ltd.	Praxair Distribution, Inc.
US8795741	March, 2016	Terminated-Denied	Mallinckrodt Hospital Products IP Ltd.	Praxair Distribution, Inc.
US8293284	March, 2016	Terminated-Denied	Mallinckrodt Hospital Products IP Ltd.	Praxair Distribution, Inc.
US8431163	March, 2016	Terminated-Denied	Mallinckrodt Hospital Products IP Ltd.	Praxair Distribution, Inc.
US8846112	March, 2016	Terminated-Denied	Mallinckrodt Hospital Products IP Ltd.	Praxair Distribution, Inc.
US8573209	March, 2015	FWD Entered	INO THERAPEUTICS LLC	Praxair Distribution, Inc.
US8776794	March, 2015	FWD Entered	INO Therapeutics LLC	Praxair Distribution, Inc.
US8573210	March, 2015	FWD Entered	INO Therapeutics LLC	Praxair Distribution, Inc.
US8776795	March, 2015	FWD Entered	INO Therapeutics LLC	Praxair Distribution, Inc.
US8291904	March, 2015	FWD Entered	INO Therapeutics LLC	Praxair Distribution, Inc.
US8282966	January, 2015	Terminated-Denied	INO Therapeutics LLC	Praxair Distribution, Inc.
US8293284	January, 2015	Terminated-Denied	INO Therapeutics LLC	Praxair Distribution, Inc.
US8795741	January, 2015	Terminated-Denied	INO Therapeutics LLC	Praxair Distribution, Inc.
US8846112	January, 2015	FWD Entered	INO THERAPEUTICS LLC	Praxair Distribution, Inc.
US8431163	January, 2015	Terminated-Denied	INO THERAPEUTICS LLC	Praxair Distribution, Inc.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8795741	MALLINCKRODT HOSP	Methods for treating patients who are candidates for inhaled nitric oxide treatment	Jun, 2029 (6 years from now)
US8282966	MALLINCKRODT HOSP	Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide	Jun, 2029 (6 years from now)
US8293284	MALLINCKRODT HOSP	Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide	Jun, 2029 (6 years from now)
US8431163	MALLINCKRODT HOSP	Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas	Jun, 2029 (6 years from now)
US8846112	MALLINCKRODT HOSP	Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation	Jun, 2029 (6 years from now)
US8846112 (Pediatric)	MALLINCKRODT HOSP	Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation	Dec, 2029 (6 years from now)
US8282966 (Pediatric)	MALLINCKRODT HOSP	Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide	Dec, 2029 (6 years from now)
US8293284 (Pediatric)	MALLINCKRODT HOSP	Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide	Dec, 2029 (6 years from now)
US8431163 (Pediatric)	MALLINCKRODT HOSP	Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas	Dec, 2029 (6 years from now)
US8795741 (Pediatric)	MALLINCKRODT HOSP	Methods for treating patients who are candidates for inhaled nitric oxide treatment	Dec, 2029 (6 years from now)
US9265911	MALLINCKRODT HOSP	Gas delivery device and system	Jan, 2031 (7 years from now)
US8573209	MALLINCKRODT HOSP	Gas delivery device and system	Jan, 2031 (7 years from now)
US8776795	MALLINCKRODT HOSP	Gas delivery device and system	Jan, 2031 (7 years from now)
US9408993	MALLINCKRODT HOSP	Nitric oxide delivery device	Jan, 2031 (7 years from now)
US8291904	MALLINCKRODT HOSP	Gas delivery device and system	Jan, 2031 (7 years from now)
US8776794	MALLINCKRODT HOSP	Nitric oxide delivery device	Jan, 2031 (7 years from now)
US8573210	MALLINCKRODT HOSP	Nitric oxide delivery device	Jan, 2031 (7 years from now)
US9295802	MALLINCKRODT HOSP	Gas delivery device and system	Jan, 2031 (7 years from now)
US8573209 (Pediatric)	MALLINCKRODT HOSP	Gas delivery device and system	Jul, 2031 (8 years from now)
US8291904 (Pediatric)	MALLINCKRODT HOSP	Gas delivery device and system	Jul, 2031 (8 years from now)
US8776795 (Pediatric)	MALLINCKRODT HOSP	Gas delivery device and system	Jul, 2031 (8 years from now)
US8776794 (Pediatric)	MALLINCKRODT HOSP	Nitric oxide delivery device	Jul, 2031 (8 years from now)
US8573210 (Pediatric)	MALLINCKRODT HOSP	Nitric oxide delivery device	Jul, 2031 (8 years from now)
US9295802 (Pediatric)	MALLINCKRODT HOSP	Gas delivery device and system	Jul, 2031 (8 years from now)
US9408993 (Pediatric)	MALLINCKRODT HOSP	Nitric oxide delivery device	Jul, 2031 (8 years from now)
US9265911 (Pediatric)	MALLINCKRODT HOSP	Gas delivery device and system	Jul, 2031 (8 years from now)
US9279794	MALLINCKRODT HOSP	Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide	Feb, 2034 (10 years from now)
US9279794 (Pediatric)	MALLINCKRODT HOSP	Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide	Aug, 2034 (11 years from now)
US9770570	MALLINCKRODT HOSP	Apparatus and method for monitoring nitric oxide delivery	May, 2036 (12 years from now)
US9770570 (Pediatric)	MALLINCKRODT HOSP	Apparatus and method for monitoring nitric oxide delivery	Nov, 2036 (13 years from now)

Do you want to check out INOMAX patents from before 2022?

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 23 December, 1999

Treatment: A method of reducing the risk of pulmonary edema in patients in need of treatment with inhaled nitric oxide; A method of providing nitric oxide therapy to a patient by verifying gas information of nit...

Dosage: GAS;INHALATION

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
100 ppm and 800 ppm	20 May, 2014	1	02 Oct, 2018	06 Jan, 2031	Deferred

Strength	Dosage	Availability
100PPM	GAS;INHALATION	Discontinued
800PPM	GAS;INHALATION	Prescription

INOMAX family patents

United States

Australia

Japan

Canada

European Union

New Zealand

Mexico

China

Spain

Portugal

Denmark

Poland

Hong Kong

Brazil

Norway

2. List of Ofirmev drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9610265	MALLINCKRODT HOSP	Reduced dose intravenous acetaminophen	Nov, 2028 (5 years from now)
US9987238	MALLINCKRODT HOSP	Reduced dose intravenous acetaminophen	Nov, 2028 (5 years from now)
US10383834	MALLINCKRODT HOSP	Reduced dose intravenous acetaminophen	Nov, 2028 (5 years from now)
US9610265 (Pediatric)	MALLINCKRODT HOSP	Reduced dose intravenous acetaminophen	May, 2029 (5 years from now)
US9987238 (Pediatric)	MALLINCKRODT HOSP	Reduced dose intravenous acetaminophen	May, 2029 (5 years from now)
US9399012	MALLINCKRODT HOSP	Reduced dose intravenous acetaminophen	Sep, 2031 (8 years from now)
US9399012 (Pediatric)	MALLINCKRODT HOSP	Reduced dose intravenous acetaminophen	Mar, 2032 (8 years from now)

Do you want to check out OFIRMEV patents from before 2022?

Drugs and Companies using ACETAMINOPHEN ingredient

Market Authorisation Date: 02 November, 2010

Treatment: Modified dosing regimen for the management of moderate to severe pain with adjunctive opioid analgesics; Modified dosing regimen for the management of mild to moderate pain or management of moderate t...

Dosage: SOLUTION;INTRAVENOUS